-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that Ultragenyx Pharmaceutical (RARE.US) closed down about 42% on Monday due to the failure of two late-stage clinical trials targeting rare bone disease assets, but investment bank Jefferies released a report saying the company is expected to rebound in 2026 due to other drug candidates in its pipeline.

Zhitongcaijing·12/31/2025 01:25:04
Listen to the news
The Zhitong Finance App learned that Ultragenyx Pharmaceutical (RARE.US) closed down about 42% on Monday due to the failure of two late-stage clinical trials targeting rare bone disease assets, but investment bank Jefferies released a report saying the company is expected to rebound in 2026 due to other drug candidates in its pipeline.